In the next few years, multicenter randomized-controlled studies on ICC immunotherapy will be an important trend in clinical research of advanced ICC.
← all excerpts
Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy.
1
—
—